Commentaries
Chronic hepatitis C
Ursodeoxycholic acid in chronic hepatitis C
APHP, Hôpital Saint-Antoine, Service dHépatologie, Université Pierre et Marie Curie Paris6, Paris, France
Correspondence to:
Raoul Poupon, Service dHépatologie, Hopital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75571 Paris Cedex 12, France; raoul.poupon@sat.ap-hop-paris.fr
Cytoprotective but anti-apoptotic
| The first 150 words of the full text of this article appear below. |
The history of ursodeoxycholic acid (UDCA) therapy has been provided by Makino and Tanaka.1 Identified in 1902 from polar bear bile by Hammarsten, UDCA was isolated and crystallised by Shoda in 1927. In 1936, its chemical structure was determined by Iwasaki at Okoyama Medical University. Several years later (1954) a chemist at Tokyo Institute of Technology, Kanazawa, described a method of synthesising UDCA from cholic acid and chenodeoxycholic acid. Three years later, Tokyo Tanabe Pharmaceutical Company launched "Urso" as a choleretic that could improve symptoms related to liver dysfunction and maldigestion. In 1961, Ishida, reporting his experience of Urso administration in chronic hepatitis, noted an improvement of liver function tests in patients receiving the bile acid. This observation was replicated several times during the following two decades in Japan. Actually, UDCA really drew the attention of the western scientific community when it was shown that it could
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
